KR20210091767A - 1,3,4-옥사디아졸론 화합물 및 의약 - Google Patents

1,3,4-옥사디아졸론 화합물 및 의약 Download PDF

Info

Publication number
KR20210091767A
KR20210091767A KR1020217017903A KR20217017903A KR20210091767A KR 20210091767 A KR20210091767 A KR 20210091767A KR 1020217017903 A KR1020217017903 A KR 1020217017903A KR 20217017903 A KR20217017903 A KR 20217017903A KR 20210091767 A KR20210091767 A KR 20210091767A
Authority
KR
South Korea
Prior art keywords
amino
phenyl
ethyl
oxadiazol
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217017903A
Other languages
English (en)
Korean (ko)
Inventor
히로타카 가미타니
히사아키 자이모쿠
요시나리 하루타
다케오 기쿠치
Original Assignee
니뽄 신야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니뽄 신야쿠 가부시키가이샤 filed Critical 니뽄 신야쿠 가부시키가이샤
Publication of KR20210091767A publication Critical patent/KR20210091767A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020217017903A 2018-11-15 2019-11-14 1,3,4-옥사디아졸론 화합물 및 의약 Pending KR20210091767A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018214950 2018-11-15
JPJP-P-2018-214950 2018-11-15
PCT/JP2019/044615 WO2020100959A1 (ja) 2018-11-15 2019-11-14 １，３，４－オキサジアゾロン化合物及び医薬

Publications (1)

Publication Number Publication Date
KR20210091767A true KR20210091767A (ko) 2021-07-22

Family

ID=70731909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217017903A Pending KR20210091767A (ko) 2018-11-15 2019-11-14 1,3,4-옥사디아졸론 화합물 및 의약

Country Status (22)

Country Link
US (1) US20220024921A1 (https=)
EP (1) EP3882239A4 (https=)
JP (1) JP7434172B2 (https=)
KR (1) KR20210091767A (https=)
CN (1) CN113302184B (https=)
AU (1) AU2019381493B2 (https=)
BR (1) BR112021009198A2 (https=)
CA (1) CA3117550A1 (https=)
CL (1) CL2021001275A1 (https=)
CO (1) CO2021007442A2 (https=)
EA (1) EA202191349A1 (https=)
EC (1) ECSP21034281A (https=)
IL (1) IL282999A (https=)
MA (1) MA54243A (https=)
MX (1) MX2021005566A (https=)
PE (1) PE20211283A1 (https=)
PH (1) PH12021551103A1 (https=)
SA (1) SA521421997B1 (https=)
SG (1) SG11202104371XA (https=)
TW (1) TWI840448B (https=)
UA (1) UA129949C2 (https=)
WO (1) WO2020100959A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4516778A4 (en) 2022-04-25 2026-04-29 Nippon Shinyaku Co Ltd COMPOUND SERVING AS A DDR1 KINASE INHIBITOR AND MEDICINE
CN117285459B (zh) * 2023-11-24 2024-02-27 上海美迪西生物医药股份有限公司 一种小分子激酶抑制剂化合物的制备方法
CN118515653B (zh) * 2024-07-23 2024-12-10 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022076A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01139581A (ja) * 1987-08-20 1989-06-01 Nissan Chem Ind Ltd テトラヒドロフタルイミド誘導体、その製法および除草剤
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
EP1797040A1 (en) 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CA2591738A1 (en) 2004-12-22 2006-06-29 Merck & Co., Inc. Process for making substituted piperidines
JP2011515337A (ja) 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼモジュレーター
GB0813740D0 (en) 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
CA2819373A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
JP2014510105A (ja) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としてのアゾール化合物
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
CN104540830A (zh) 2012-06-07 2015-04-22 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂
GB201814151D0 (en) 2018-08-31 2018-10-17 Ucl Business Plc Compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022076A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors

Non-Patent Citations (73)

* Cited by examiner, † Cited by third party
Title
Andina 등, J. Allergy. Clin. Immunol., 2009, 123, 603-611.
Bajaj 등, Virology, 2006, 351, 18-28.
Bellon 등, Blood, 2016, 127, 2439-2450.
Braso-Maristany 등, Nat. Med., 2016, 22, 1303-1313.
Brunen 등, Mol. Cancer Ther., 2018, 17, 849-857.
Burger 등, J. Med. Chem., 2015, 58, 8373-8386.
Chen 등, Blood, 2009, 114, 4150-4157.
Cheng 등, PLoS Pathog., 2009, 5, e1000324.
Chiocchetti 등, Haematologica, 2005, 90, 1453-1462.
de Vries 등, Eur. Respir. J., 2015, 45, 1745-1748.
Egli 등, PLoS One, 2015, 10, e0142741.
Fan 등, Mol. Med. Rep., 2017, 16, 4603-4612.
Foulks 등, Neoplasia, 2014, 16, 403-412.
Fujii 등, Int. J. Cancer, 2005, 114, 209-218.
He 등, Med. Oncol., 2009, 26, 303-308.
Herzog 등, Neuro-Oncol., 2015, 17, 223-242.
Hsi 등, Leuk. Lymphoma, 2008, 49, 2081-2090.
Iqbal 등, Oncotarget, 2016, 7, 33192-33201.
Jackson 등, Cell Immunol., 2012, 272, 200-213.
Jimenez-Garcia 등, Oncotarget, 2017, 8, 58872-58886.
Jimenez-Garcia 등, Sci. Rep., 2016, 6, 38079.
Jin 등, PLoS One, 2012, 7, e48575.
Kaneto 등, Mediators Inflamm., 2010, 2010, 453892.
Keane 등, Blood Cancer J., 2015, 5, e325.
Kim 등, Pharmacol. Res., 2013, 70, 90-101.
Kirschner 등, J. Natl. Cancer. Inst., 2014, 107, dju407.
Kuo 등, Am. J. Cancer Res., 2016, 6, 2489-2501.
Lee 등, Genomics, 2006, 88, 496-503.
Li 등, Cancer Res., 2006, 66, 6741-6747.
Li 등, Oncol. Rep., 2010, 24, 997-1004.
Liao 등, J. Orthop. Res., 2016, 34, 1185-1194.
Lim 등, Mol. Hum. Reprod., 2017, 23, 428-440.
Lin 등, Int. Immunopharmacol., 2015, 28, 859-865.
Liu 등, J. Surg. Oncol., 2010, 102, 683-688.
Liu 등, Oncotarget, 2015, 6, 8019-8035.
Mahalingam 등, Br. J. Cancer, 2011, 105, 1563-1573.
Martin-Sanchez 등, PLoS One, 2014, 9, e112148.
Mary Photini 등, Exp. Cell Res., 2017, 359, 275-283.
Mawas 등, Int. J. Oncol., 2017, 50, 1029-1034.
Mazzacurati 등, Oncotarget, 2015, 6, 40141-40157.
Mikkers 등, Mol. Cell. Biol., 2004, 24, 6104-6115.
Mondello 등, J. Hematol. Oncol., 2014, 7, 95.
Mou 등, Int. J. Oncol., 2016, 49, 2116-2126.
Mukaida 등, Cancer Sci., 2011, 102, 1437-1442.
Narlik-Grassow 등, Carcinogenesis., 2012, 33, 1479-1486.
Nawijn 등, Nat. Rev. Cancer, 2011, 11, 23-34.
Nga 등, Int. J. Exp. Pathol., 2010, 91, 34-43.
Padi 등, Oncotarget, 2017, 8, 30199-30216.
Paino 등, Clin. Cancer Res., 2017, 23, 225-238.
Park 등, J. Virol., 2015, 89, 10073-10086.
Paulin 등, Circulation, 2011, 123, 1205-1215.
Peltola 등, Neoplasia, 2009, 11, 629-636.
Peng 등, PLoS One, 2013, 8, e76693.
Perera 등, Sci. Transl. Med., 2014, 6, 223ra22.
Rainio 등, Virology, 2005, 333, 201-206.
Rimon 등, Int. J. Oncol., 2004, 24, 1325-1338.
Rogers 등, Sci. Signal., 2011, 4, rs9.
Shannan 등, Oncotarget, 2016, 7, 54897-54912.
Shen 등, Dig. Dis. Sci., 2012, 57, 1822-1831.
Shin 등, Am. J. Respir. Cell Mol. Biol., 2012, 46, 488-497.
Sutcliffe 등, PLoS Pathog., 2012, 8, e1002801.
Szydlowski 등, Blood, 2017, 130, 1418-1429.
Velazquez 등, Mol. Neurodegener., 2016, 11, 52.
Vries 등, Eur. Respir. J., 2016, 47, 783-791.
Wang 등, J. Allergy Clin. Immunol., 2012, 130, 932-944.
Wang 등, Oncotarget, 2017, 8, 88320-88331.
Warnecke-Eberz 등, Anticancer Res., 2009, 29, 4451-4455.
Weirauch 등, Neoplasia, 2013, 15, 783-794.
Xie 등, Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2014, 39, 649-657.
Xu 등, Cancer Cell Int., 2018, 18, 22.
Yang 등, Blood, 2012, 120, 3491-3500.
Yang 등, Pathol. Res. Pract., 2017, 213, 322-326.
Zhang 등, Pharmacol. Rep., 2017, 69, 1270-1281.

Also Published As

Publication number Publication date
AU2019381493B2 (en) 2024-10-31
SA521421997B1 (ar) 2025-04-10
JP7434172B2 (ja) 2024-02-20
PH12021551103A1 (en) 2021-11-22
CL2021001275A1 (es) 2021-11-05
JPWO2020100959A1 (ja) 2021-10-07
ECSP21034281A (es) 2021-06-30
PE20211283A1 (es) 2021-07-19
EP3882239A1 (en) 2021-09-22
US20220024921A1 (en) 2022-01-27
MA54243A (fr) 2021-09-22
AU2019381493A1 (en) 2021-06-03
CN113302184B (zh) 2024-11-22
TWI840448B (zh) 2024-05-01
UA129949C2 (uk) 2025-09-24
TW202031649A (zh) 2020-09-01
WO2020100959A1 (ja) 2020-05-22
EP3882239A4 (en) 2022-08-10
IL282999A (en) 2021-06-30
CN113302184A (zh) 2021-08-24
SG11202104371XA (en) 2021-05-28
EA202191349A1 (ru) 2021-08-10
CA3117550A1 (en) 2020-05-22
CO2021007442A2 (es) 2021-06-21
MX2021005566A (es) 2021-07-15
BR112021009198A2 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
CN106170486B (zh) 新吲唑甲酰胺、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN105899505B (zh) 用于治疗自身免疫病症的吡唑
US9242977B2 (en) Trk-inhibiting compound
CA2948589C (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
CN104812748B (zh) 二氢吡唑gpr40调节剂
CN111615512A (zh) 引起egfr降解的化合物，用于抗癌
CN114828959A (zh) 3-(5-甲氧基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CN102666489B (zh) 鞘氨醇激酶抑制剂
CN107074805B (zh) 用于治疗疾病的gls1抑制剂
KR102679517B1 (ko) Tnf 알파의 조정제로서 유용한 시클릭 화합물
US9067923B2 (en) Substituted quinoxalines
US10112944B2 (en) Heterocyclic compounds useful as inhibitors of TNF
TW201706274A (zh) 吡咯［２，３－ｄ］嘧啶基、吡咯［２，３－ｂ］吡基和吡咯［２，３－ｂ］吡啶基丙烯醯胺及其環氧化物
CN102639513A (zh) 鞘氨醇激酶抑制剂
TWI840448B (zh) 二唑酮化合物及醫藥
CN112368282A (zh) 氮杂苯并咪唑化合物和医药
JP7808733B2 (ja) 置換オキソイソインドリニルピペリジン－２，６－ジオン化合物
HK40051487B (zh) 1,3,4-恶二唑啉酮化合物和药物
CN118103352A (zh) Kif18a的螺吲哚啉抑制剂
HK40051017A (en) 1,3,4-oxadiazolone compound and medicine
HK40051487A (en) 1,3,4-oxadiazolone compound and medicine
HK40113963A (zh) Pd-1/pd-l1抑制剂
HK40017188B (zh) Pd-1/pd-l1 抑制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701